TB-500 tracker
Educational reference for TB-500. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
2 h
Tmax
1 h
Category
peptide
Also known as: thymosin beta-4 fragment
> PLACEHOLDER — pending clinical review by licensed pharmacist. TB-500 is a synthetic fragment of thymosin beta-4, a naturally occurring actin-sequestering protein involved in cytoskeletal organisation and cell migration. Preclinical studies have suggested roles in wound healing, angiogenesis, and anti-inflammatory signalling. Its plasma half-life is approximately 2 hours, which has led to variable dosing protocols in practice. TB-500 is often discussed alongside BPC-157 in peer protocols for soft-tissue recovery. However, controlled human trials are scarce, and its safety profile outside of research settings is not well characterised. Users who track TB-500 should document dosing frequency, injection sites, and subjective recovery outcomes.
Mechanism
A synthetic fragment related to thymosin beta-4. In preclinical work it is described as an actin-binding peptide implicated in cell migration and tissue-repair signaling; human mechanistic data are limited.
Research summary
Evidence is largely preclinical and drawn from thymosin beta-4 research. It is not FDA-approved for human therapeutic use, and controlled human clinical data are sparse. In July 2026 an FDA advisory committee (the Pharmacy Compounding Advisory Committee) voted to recommend this compound for the 503A bulk-compounding list. That recommendation is non-binding and is not FDA approval — it would still require formal rulemaking, and no approved clinical evidence of safety or efficacy exists.
Dosing in the literature
No established human clinical regimen exists; human pharmacokinetics are not well characterized. This summary does not provide dosing.
Reported side effects
The human safety profile is not well established given the lack of controlled trials. Sourcing and purity are recurring quality concerns.
Stacking notes
Frequently paired anecdotally with BPC-157 for recovery, without controlled human evidence to support the combination.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- Thymosin beta-4 tissue-repair overview · peer-reviewed review article (2012)parent molecule literature; search PubMed for thymosin beta-4
- Regulatory status note · FDA / regulatory guidance (2023)not an approved drug; verify current status
References
- Thymosin beta-4 overviewDOI: 10.1196/annals.1415.021
Track TB-500 in TrackPep
Reconstitution calculator, interactive body-map rotation, side-effect timeline, weight trends, and a private log — all in one place. Free to try.